Nav: Home

Fatty liver disease pandemic needs 'gold standard' human-relevant research

July 18, 2018

BRUSSELS (16 July 2018) - A new study by scientists from the Vrije Universiteit Brussel calls for a new gold standard in research to treat non-alcoholic steatohepatitis (NASH), an obesity-linked chronic liver disease impacting millions of people of all ages worldwide, which can progress to liver cancer if untreated, creating a massive strain on an already overburdened healthcare system. The study, published today in Pharmacological Research, proposes a human-specific roadmap to better understand the biological mechanisms behind NASH, a crucial missing link in the effort to develop effective, and urgently-needed, treatments for the disease. 

Dr Robim Rodrigues and Prof Tamara Vanhaecke of the Vrije Universiteit Brussel, lead authors on the study, commented that "In vitro models that reflect population diversity and specific mechanisms of the disease are already valuable tools today. Modern techniques, including transcriptomics, proteomics, and metabolomics, are rapidly becoming more reliable and may therefore provide insights into the mechanistic background of NASH." Dr Rodrigues explains that several drugs in development for NASH have been tested using in vitro models, clearly indicating the value of these systems in NASH R&D. He is optimistic that further development of predictive, human-based tools will provide a more cost-effective and reliable methodology for much-needed drug development for NASH liver disease. 

Although the causes of NASH are well known, decades of animal research and different approaches to create animal models (dietary modification, chemical injury and gene manipulation) have largely failed to reveal the underlying disease mechanisms, and recapitulate at most a handful of features of the human condition. Difficulties translating data from animal models to humans are well known; National Institutes of Health (NIH) Director Francis Collins stated that over 95% of new drugs that pass animal testing fail to achieve any clinical efficacy when trialled in people or worse, present with life-threatening side-effects. This was seen with Vioxx and other COX2-inhibitors (used as powerful anti-inflammatory drugs), fialuridine (used to treat hepatitis B), bitopertin (for treating patients with Schizophrenia), or darapladib (for atherosclerosis), to name a few among many. 

Given the obesity pandemic, and the fact that NASH is caused by fat accumulation in the liver, the incidence of the disease is on the rise. Coupled with the absence of any effective treatments for NASH, there is a growing global recognition of this 'silent epidemic', culminating in the first 'International NASH Day' in June of this year. Clearly, the time is now to dedicate more funding for human-relevant in vitro and systems biology tools described in this paper, in order to enable better understanding of the mechanism of NASH, identifying drug targets, and ultimately developing new drugs. 
-end-
The review by Boeckmans et al., Human-based systems: Mechanistic NASH modelling just around the corner?, was supported by funding from the BioMed21 Collaboration.

Humane Society International

Related Drugs Articles:

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.
Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.
Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.
Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.
People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.
Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.
Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.
Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.
New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.
New TB drugs possible with understanding of old antibiotic
Tuberculosis, and other life-threatening microbial diseases, could be more effectively tackled with future drugs, thanks to new research into an old antibiotic by the University of Warwick and the Francis Crick Institute.
More Drugs News and Drugs Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.